Sex differences in hospital readmission among colorectal cancer patients. by González Ruiz, Juan Ramón et al.
RESEARCH REPORT
Sex differences in hospital readmission among colorectal
cancer patients
Juan Ramon Gonza´lez, Esteve Fernandez, Vı´ctor Moreno, Josepa Ribes, Merce` Peris, Matilde
Navarro, Maria Cambray, Josep Maria Borra`s
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
See end of article for
authors’ affiliations
. . . . . . . . . . . . . . . . . . . . . . .
Correspondence to:
Dr E Fernandez, Cancer
Prevention and Control
Unit, Institut Catala`
d’Oncologia, Avda. Gran
Vı´a s/n, km 2,7, 08907
L’Hospitalet de Llobregat,
Barcelona, Spain;
efernandez@ico.scs.es
Accepted for publication
28 December 2004
. . . . . . . . . . . . . . . . . . . . . . .
J Epidemiol Community Health 2005;59:506–511. doi: 10.1136/jech.2004.028902
Background: While several studies have analysed sex and socioeconomic differences in cancer incidence
and mortality, sex differences in oncological health care have been seldom considered.
Objective: To investigate sex based inequalities in hospital readmission among patients diagnosed with
colorectal cancer.
Design: Prospective cohort study.
Setting: Hospital Universitary in L’Hospitalet (Barcelona, Spain).
Participants: Four hundred and three patients diagnosed with colorectal between January 1996 and
December 1998 were actively followed up until 2002.
Main outcome measurements and methods: Hospital readmission times related to colorectal cancer after
surgical procedure. Cox proportional model with random effect (frailty) was used to estimate hazard rate
ratios and 95% confidence intervals of readmission time for covariates analysed.
Results: Crude hazard rate ratio of hospital readmission in men was 1.61 (95% CI 1.21 to 2.15). When
other significant determinants of readmission were controlled for (including Dukes’s stage, mortality, and
Charlson’s index) a significant risk of readmission was still present for men (hazard rate ratio: 1.52, 95%
CI 1.17 to 1.96).
Conclusions: In the case of colorectal cancer, women are less likely than men to be readmitted to the
hospital, even after controlling for tumour characteristics, mortality, and comorbidity. New studies should
investigate the role of other non-clinical variable such as differences in help seeking behaviours or
structural or personal sex bias in the attention given to patients.
C
olorectal cancer is the leading site of cancer in non-
smokers (sexes combined) in Western countries.1 2
Although incidence, mortality, and survival trends, as
well as risk factors of colorectal cancer have been extensively
studied, less attention has been paid to research on health
care services delivered to patients affected from this disease.
Sex differences in health, assessed in terms of mortality and
morbidity, have been reported in most developed countries
over recent decades.3–6 In Spain, the reduction of social
inequalities in health and in access to health care is a matter
of concern.7 8 Most of the reported inequalities refer to self
perceived health and lifestyles,9 10 or in the access to
preventive services11 but not in the area of access or use of
hospital services.
While several studies have analysed sex and socioeconomic
differences in cancer incidence and mortality,12 sex inequal-
ities in oncological health care use have been rarely
considered.13–15 The aim of this study was to investigate sex
based inequalities in hospital readmission among patients
diagnosed with colorectal cancer attending a university
hospital.
METHODS
Study population and variables of interest
The study took place in the Hospital de Bellvitge, a 960 bed
public university hospital in the metropolitan area of
Barcelona, Spain. Between January of 1996 and December
1998, a total of 523 patients with incident colorectal cancer
were identified. This study is based on 403 patients who had
an operation. The local ethics committee for clinical
investigation approved the study and all the patients gave
written informed consent to participate. Other 120 (23%)
patients were excluded because they died or were released
before they were approached (n=74), refused to participate
in the study (n=13), had incomplete information or inter-
views (n=27), or lived at 100 km or more from the hospital
(n=6). No differences between them and the patients
included according to age, sex, Dukes’s stage, tumour site,
and overall survival were seen (data not shown).
The outcome variable in this study is readmission,
considering it as a potential recurrent event (colorectal
cancer patients may have several readmissions after dis-
charge). The date of surgery was taken as the beginning of
the study period. Patients were actively followed up until
June 2002. Consequently, the length of follow up can differ
for each patient, depending on the surgery date. Some
premature censoring might also occur because of death,
migration, or change of hospital. The first readmission time
has been considered as the time between the date of the
surgical procedure and the first readmission to hospital
related to colorectal cancer. The following readmission times
have been considered as the difference between the last
discharge date and the current hospitalisation date. In total,
1125 readmission events were recorded. As comorbidity may
influence the likelihood of hospital readmission,16 we have
only considered readmissions related to colorectal cancer. We
obtained this information from the discharge diagnosis
registered in the minimum basic dataset maintained by the
department of clinical documentation. The following diag-
nostic codes of the International Classification of Disease, 9th
revision clinical modification, were considered: 153–155, 159,
196–199, 202, 211, 230, 235, 280, 281, 284, 287, 288, 453, 513,
522, 553, 557, 558, 560, 562, 565, 569, 571, 789, 996–999; and
the procedures: V58, V55, and V71. Hence we excluded 264
re-hospitalisations because the main diagnostic or procedures
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were not related to colorectal cancer. Thus, the final dataset
consisted on 861 re-hospitalisations recorded on the 403
patients included in the study.
The main independent variable was sex, and other
variables considered as potential confounders were age
(,60, 60–74, >75 years), tumour site (rectum, colon),
tumour stage (Dukes’s classification: A–B, C, or D), type of
treatment (chemotherapy, radiotherapy), distance from
living place to hospital ((30 km, .30 km), educational
level (less than primary, primary, secondary, university).
Given that radiotherapy is an exclusive treatment for patients
with rectal cancer, to analyse both variables in multivariate
models we have created a variable that combines both
radiotherapy and tumour site (colon, rectum treated with
radiotherapy, and rectum treated without radiotherapy). To
adjust the risk of readmissions for comorbidity, we have
calculated Charlson’s index16 modified by Librero et al17 that
incorporates the information from the ICD-9-CM. In addi-
tion, to take into account the differences in survival, we have
also incorporated it in the models.
Statistical analysis
Readmissions have been analysed both in frequency and time
elapse between the two of them. As several readmissions can
occur for the same patient, these events are potentially
correlated and statistical analysis must account for this. We
used a graphical method that compares different non-
parametric estimators of the distribution function of hospi-
talisation times18 19 to confirm the correlation between the
times of re-hospitalisation for each patient.19 Then hospital-
isation times were modelled with a proportional hazard’s
model that included a random effect (frailty) to account
for the within subject correlation between events.20 21 Hazard
rate ratios (HR) and 95% confidence intervals (CI) of
readmission were calculated for each covariate.22 Charlson’s
index was modelled as a time dependent covariate. One
and three year probability of readmission and the median
time of readmission were calculated by means of a non-
parametric estimation under a gamma frailty model.19 Yates’s
corrected x2 test or t test were used to compare the variable
distributions between sexes, as appropriate. The Mann-
Whitney U or Kruskall-Wallis tests were used to compare
the number of hospital readmission for the variables studied.
All analysis was done using both survival and survrec
libraries implemented in R packages.23
RESULTS
Table 1 shows the patient characteristics by sex. No
significant differences between men and women were seen
in any of the variables analysed, except Charlson’s comor-
bidity index. Men tended to be older, with less advanced
tumour stage, and received less frequently chemotherapy.
Table 2 shows the distribution of hospital readmissions.
Most of the patients (70.7% of men and 82.3% of women)
had none or one readmission and only about 5% of subjects
had more than five readmissions. Male patients had, on
average, more readmissions than women did (2.3 compared
with 1.9, p=0.060). Readmission tended to be more frequent
in patients ,60 years (p=0.072) and a higher number of
hospitalisations was associated with more advanced tumour
stages and treatment with chemotherapy (p,0.001). Patients
with rectal cancer receiving radiotherapy have more readmis-
sions (p=0.022). Patients who died during follow up had a
greater mean number of readmissions (p,0.001). Figures 1
and 2 show that the estimated probability of readmission is
always higher for men than for women independently of
Dukes’s tumour stage or mortality.
Table 3 shows the analysis of time to readmission for the
variables included in the study using a non-parametric
estimator that accounts for within patient correlation of
readmission. The univariate and multivariate (mutually
adjusted) Cox frailty models that provides the hazard risk
of readmission for each variable are also shown in this table.
The one year probability of rehospitalisation was 0.39 in men
and 0.32 in women. Median time between readmissions
was almost twofold in women than men. This corresponds
to a crude 61% (95% CI: 21% to 115%) excess risk of
rehospitalisation for men (table 3). Advanced tumour stage,
chemotherapy, high educational level, mortality, and high
comorbidity were also associated with smaller times between
readmissions (table 3). Furthermore, male sex was still
associated with time to rehospitalisation (HR=1.52; 95% CI:
1.17 to 1.96) after allowance for stage, comorbidity, and
mortality. No effect modification between sex and the rest of
predictors of readmission in the final model was present
(data not shown).
DISCUSSION
This study has assessed the time to readmission to the
hospital after the date of surgery. The most intriguing finding
seen is the sex difference in frequency and time to
readmission. Women had a lower probability of readmission
to the hospital, even after controlling for other sociodemo-
graphic and disease related variables. Several factors could
Table 1 Distribution of 403 colorectal cancer patients
according to sex and selected variables
Men Women
p Value*n (%) n (%)
Age (y)
Average 65.4 63.8 0.123
,60 63 (26.4) 48 (29.3)
60–74 119 (49.8) 75 (45.7)
>75 57 (23.8) 41 (25.0) 0.710
Tumour site
Rectum 84 (35.1) 67 (40.9)
Colon 155 (64.9) 97 (59.1) 0.290
Dukes’s stage
A–B 115 (48.1) 65 (39.6)
C 81 (33.9) 67 (40.9)
D 43 (18.0) 32 (19.5) 0.226
Chemotherapy
Yes 102 (42.7) 84 (51.2)
No 137 (57.3) 80 (48.8) 0.112
Stage II and III rectum only 37 (67.3) 33 (71.7)
Stage III colon only 30 (63.8) 25 (69.4)
Radiotherapy
Yes 45 (18.8) 34 (20.7)
No 194 (81.2) 130 (79.3) 0.730
Stage II and III 41 (74.5) 33 (71.7)
Distance
Average (km) 21.6 26.1 0.601
(30 km 211 (88.3) 146 (89.6)
.30 km 28 (11.7) 17 (10.4) 0.810
Length of hospitalisation
Average (days) 12.35 12.27 0.904
Mortality
No 170 (71.1) 123 (75.0)
Yes 69 (28.9) 41 (25.0) 0.457
Educational level
Less than primary 104 (43.5) 72 (43.9)
Primary 102 (42.7) 75 (45.7)
Secondary 23 (9.6) 13 (7.9)
University 10 (4.2) 4 (2.4) 0.711
Charlson index`
0 375 (68.3) 202 (64.7)
1–2 36 (6.6) 10 (3.2)
>3 138 (25.1) 100 (32.1) 0.018
Length of follow up
Average (y) 3.81 3.78 0.795
*Comparison uses a x2test with Yates’s correction for categorical
variables and t test for continuous. Results only for rectal cancer.
`Distribution for all readmissions.
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contribute to explain this finding. Firstly, sex differences
in adverse effects caused by chemotherapy could influence
the likelihood of re-hospitalisation. Women may experience
higher toxicity than men to chemotherapy.24 However, the
logical consequence would have been more, but not less,
re-hospitalisations as seen in our study. Other possible
explanation for the differences in readmissions could be a
differential rate of complications after surgery or radio-
therapy. Postoperative mortality has been analysed and
no clear sex related pattern emerged. Thus, this does not
contribute to readmissions rates among women. Although we
have included several relevant variables like stage at
diagnosis, type of treatment, tumour site, and comor-
bidity in the analysis, we cannot exclude the possibility
of residual confounding attributable to unknown factors
that account for the association observed. In this sense,
the random effect model used in the analysis may capture
this effect attributable to non-observed covariates besides
that it takes into account for correlation within recurrent
events.
Although no meaningful significant difference in survival
by sex was found (HR of death of 0.83, 95% CI 0.68 to 1.02,
Table 2 Frequency and mean number of hospital readmissions according to selected variables
Number of hospital readmission
p Value*0 n(%) 1 n(%) 2 n(%) 3 n(%) 4 n(%) >5 n(%) mean
Sex
Female 87 (53.0) 48 (29.3) 11 (6.7) 8 (4.9) 5 (3.0) 5 (3.0) 1.9
Male 112 (46.9) 57 (23.8) 34 (14.2) 13 (5.4) 10 (4.2) 13 (5.4) 2.3 0.060
Age
,60 47 (42.3) 32 (28.8) 11 (9.9) 7 (6.3) 8 (7.2) 6 (5.4) 2.4
60–74 98 (50.5) 44 (22.7) 27 (13.9) 12 (6.2) 7 (3.6) 6 (3.1) 2.1
>75 54 (55.1) 29 (29.6) 7 (7.1) 2 (2.0) 0 (0.0) 6 (6.1) 1.8 0.072
Tumour site
Colon 129 (51.2) 66 (26.2) 27 (10.7) 15 (6.0) 7 (2.8) 8 (3.2) 2.0
Rectum 70 (46.4) 39 (25.8) 18 (11.9) 6 (4.0) 8 (5.3) 10 (6.6) 2.3 0.200
Dukes’s stage
A–B 103 (57.2) 43 (23.9) 16 (8.9) 8 (4.4) 7 (3.9) 3 (1.7) 1.8
C 67 (45.3) 40 (27.0) 20 (13.5) 7 (4.7) 6 (4.1) 8 (5.4) 2.2
D 29 (38.7) 22 (29.3) 9 (12.0) 6 (8.0) 2 (2.7) 7 (9.3) 2.7 ,0.001
Chemotherapy
No 125 (57.6) 51 (23.5) 22 (10.1) 7 (3.2) 4 (1.8) 8 (3.7) 1.8
Yes 74 (39.8) 54 (29.0) 23 (12.4) 14 (7.5) 11 (5.9) 10 (5.4) 2.5 ,0.001
Radiotherapy
No 39 (52.7) 19 (25.7) 6 (8.1) 2 (2.7) 2 (2.7) 6 (8.1) 2.0
Yes 31 (40.3) 20 (26.0) 12 (15.6) 4 (5.2) 6 (7.8) 4 (5.2) 2.3 0.022
Distance
(30 km 174 (48.7) 96 (26.9) 43 (12.0) 16 (4.5) 14 (3.9) 14 (3.9) 2.1
.30 km 24 (53.3) 9 (20.0) 2 (4.4) 5 (11.1) 1 (2.2) 4 (8.9) 2.2 0.818
Mortality
No 162 ( 55.3) 72 ( 24.6) 29 (9.9) 11 (3.8) 9 (3.1) 10 (3.4) 1.9
Yes 37 ( 33.6) 33 ( 30.0) 16 ( 14.5) 10 (9.1) 6 (5.5) 8 (7.3) 2.8 ,0.001
Educational level
Less than primary 83 (47.2) 49 (27.8) 24 (13.6) 9 (5.1) 6 (3.4) 5 (2.8) 2.0
Primary 91 (51.4) 45 (25.4) 16 (9.0) 8 (4.5) 7 (4.0) 10 (5.6) 2.2
Secondary 21 (58.3) 8 (22.2) 2 (5.6) 1 (2.8) 2 (5.6) 2 (5.6) 2.0
University 4 (28.6) 3 (21.4) 3 (21.4) 3 (21.4) 0 (0.0) 1 (7.1) 3.4 0.175
*p Value for Mann-Whitney U test or Kruskal-Wallis test. Results only for rectal cancer.
0.0
0.2
0.4
0.6
0.8
1.0
70
Time (months)
Dukes's A–B women
Dukes's C women
Dukes's D women
Dukes's D men
Dukes's C men
Dukes's A–B men
Pr
ob
ab
ili
ty
 o
f h
os
pi
ta
l r
ea
dm
is
si
on
6050403020100
Figure 1 Probability of hospital readmission according to Dukes’s
stage and sex.
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for women compared with men, adjusted for tumour stage,
age, tumour site, and surgical procedure), mortality was
associated with a higher risk of readmission (HR=2.24,
table 3). Factors that could explain the lower probability of
readmission in women are beyond the clinical and biological
variables studied. Differentials in the social role of women as
well as sex based differences in the perception of symptom
control could offer alternative explanations.25–27 Although it is
not possible to explore these alternative pathways with our
data, a lower probability of hospital use by women has been
reported in this population after excluding pregnancy and
delivery related hospitalisations, and adjusting for self
perceived health, chronic conditions, and sociodemographic
variables.28 This finding from a health survey with a sample
from the general population is consistent with our finding
and points to a more general explanation than medical or
demographic factors.26 27
Around half of the patients included in this study required
a readmission to the hospital with a mean of 2.1 re-
admissions. Clearly, the main factor associated was stage at
diagnosis, as shown in figure 1. Age was inversely related to
the probability of readmission, probably because of differ-
ences in chemotherapy use according to age, as shown by the
absence of differences when other factors are also controlled
for in the analysis. Radiotherapy among rectal cancer patients
was associated with higher probability of readmission.
In Spain, the universal health coverage warrants the
provision of health care to all population and no meaningful
inequalities in health care use exist although some inequal-
ities in the access to some specific services (dentists,
optometrist) persist.8–10 Although distance to hospital has
been associated with differences in oncological care,29 30 in
our study this has not been found.
Stage at diagnosis and comorbidity were associated with
higher probability of being readmitted to the hospital, which
is consistent with their known role in the therapeutic
decision procedure and in the prognosis in cancer.
Comorbidity was taken into account using Charlson’s index,
which was included in the model as a time dependent
covariable to further adjust for these conditions. Comorbidity
has been associated with readmission to hospital16 as well as
with length of stay31 32 or complications of treatment.33–35 In
our study, a higher Charlson’s index was seen among women
at every admission to the hospital. Charlson’s index was
associated with a higher probability of readmission but did
not modify the risk of readmission of women when it was
controlled for. Moreover, it is interesting to note that the use
of chemotherapy and radiotherapy in stage III, colon cancer,
and in stage II and III, rectal cancer, is similar to that
reported in the literature.36 37 As in our case, age and
comorbidity were identified as predictor factors of not being
offered chemotherapy or radiotherapy.
Table 3 Probability, median, and hazard ratios of readmission for selected variables
n(%)
Median time
to readmission
(days)
Hazard ratio and 95% CI
Univariate model Multivariate model*
Sex
Female 164 (40.7) 1427 1 1
Male 239 (59.3) 799 1.61 (1.21,2.15) 1.52 (1.17,1.96)
Age
,60 111 (27.5) 799 1 1
60–74 194 (48.1) 1230 0.84 (0.61,1.16) 0.90 (0.66,1.21)
>75 98 (24.3) 1188 0.85 (0.57,1.26) 1.06 (0.70,1.60)
p for trend: 0.360 p for trend: 0.760
Tumour site
Colon 252 (62.5) 1116 1
Rectum 151 (37.5) 1022 1.16 (0.88,1.54)
Dukes’s stage
A–B 180 (44.7) 2175 1 1
C 148 (36.7) 1073 1.49 (1.12,1.99) 1.15 (0.85,1.56)
D 75 (18.6) 199 3.37 (2.39,4.75) 1.78 (1.20,2.64)
p for trend: ,0.001 p for trend: ,0.001
Chemotherapy
No 217 (53.8) 1427 1 1
Yes 186 (46.2) 734 1.42 (1.08,1.86) 1.34 (0.96,1.86)
Radiotherapy
No 77 (51.0) 1188 1 1.23` (0.88,1.72)
Yes 74 (49.0) 589 1.25 (0.79,1.96) 1.41` (1.00,1.99)
Distance
(30 km 381 (94.8) 1073 1 1
.30 km 21 (5.2) 1128 1.01 (0.68,1.62) 1.07 (0.72,1.59)
Mortality
No 293 (72.7) 1736 1 1
Yes 110 (27.3) 218 3.21 (2.46,4.19) 2.24 (1.66,3.02)
Educational level
Less than primary 176 (43.7) 819 1 1
Primary 177 (43.9) 1188 1.12 (0.84,1.50) 0.92 (0.70,1.20)
Secondary 36 (8.9) NA 0.87 (0.53,1.45) 0.62 (0.38,1.01)
University 14 (3.5) 227 2.77 (1.44,5.32) 1.64 (0.92,2.92)
p for trend: 0.042 p for trend: 0.850
Charlson index1
0 577 (67.0) 1 1
1–2 46 (5.3) 1.66 (0.90,3.05) 1.45 (0.89,2.36)
>3 250 (27.7) 2.25 (1.69,2.99) 1.31 (1.01,1.70)
p for trend: ,0.001 p for trend: 0.028
*Cox gamma frailty model adjusted for all the variables in the table. Results only for rectal cancer. `Given the
correlation between radiotherapy treatment and tumour site we have combined them into a variable: hazard ratio
for rectum cancer with and without radiotherapy and referring to colon cases without radiotherapy treatment.
1Distribution for all readmissions to hospital. NA, not available.
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There are some limitations to our study. Firstly, we have
analysed readmission to the hospital where all patients were
diagnosed and treated. Some patients, especially those not
living in the proximity of the hospital may have been
admitted to other hospital. With the available data it is not
possible to control for this potential source of bias. Moreover,
we have analysed separately the readmission from those
patients living near ((30 km) and far (.30 km) from the
hospital, and no differences in the mean number of
readmissions was present. Furthermore, we excluded from
the study those patients living 100 km or more from the
hospital. Admissions to other hospitals would have been a
problem only in the case of presenting a differential pattern
by sex, which seems unlikely.
On the other hand, we have used strong predictors of
readmission and mortality collected in the framework of a
case-control study, thus improving their accuracy and
validity. Finally, the Cox frailty model used allows us to
study a recurrent phenomenon, such as hospital readmission
for colorectal cancer, taking into account the potential
correlation between the events.
Use of health services in cancer patients has not been a
very active area of study in recent years. However, improving
monitoring of oncological care use is especially important in
the context of a national health service, which is aimed at
facilitating an equal use of health services according to the
need.38 Although countries in Europe perform comparatively
well in access to health care and use of health services,39 sex
inequalities have not disappeared as this study shows.
We conclude that, in the case of colorectal cancer, women
are less likely than men to be readmitted to the hospital, even
after controlling for tumour characteristics and comorbidity.
Thus, new studies should investigate the role of other non-
clinical variable such as differences in help seeking beha-
viours or structural or personal sex bias in the attention given
to patients.
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Professor Aaron Antonovsky (1923–1994): the father of the salutogenesis
T
en years ago Aaron Antonovsky died after a short period of disease. His death meant a
break in the leadership of a new innovative direction in public health research. His
fundamental contribution was to raise the philosophical ‘‘salutogenic’’ question of what
creates health and search for ‘‘the origin of health’’ rather than to look for the causes of disease.
He was born in Brooklyn New York studied sociology and later became professor and head of
the department of sociology of health at the faculty of health sciences of the Ben-Gurion
University in Israel. Antonovsky had the salutogenic idea while conducting an epidemiological
study on problems in the menopause of women in different ethnic groups in Israel. One of
these groups shared a common experience—they had survived the concentration camps of the
second world war. To his surprise he found that these women had the capability of maintaining
good health and lead a good life despite all they had gone through. Antonovsky stated that
disease and stress occur everywhere and all the time and it was surprising that organisms were
able to survive at all with this constant mass exposure. The question that came to his mind was
how we can survive despite all this. In his world health is relative on a continuum and the key
research question is what causes health (salutogenesis) not what are the reasons for disease
(pathogenesis). The salutogenic perspective focuses on three aspects. Firstly, the focus is on
problem solving/finding solutions. Secondly, it identifies generalised resistance resources that
help people to move in the direction of positive health. Thirdly, it identifies a global and
pervasive sense in individuals, groups, populations, or systems that serves as the overall
mechanism or capacity for this process, the sense of coherence (SOC). Today almost 25 years
have passed since the question first was raised and it is about time to draw the conclusions of
how far research has come. Presently there is a review of this research undertaken at the Nordic
school of public health. The preliminary results prove that SOC develops through life time. SOC
increases through the life span and it has strong positive correlations to perceived health,
mental health, and quality of life. The Institute of Medicine in USA stated in 2003 that one of
the most pertinent needs for the education of health professionals for the 21st century is the
necessity of finding a coherent health concept—the salutogenic model would perhaps serve
such a purpose.
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